Ditchcarbon
  • Contact
  1. Organizations
  2. Mylan, Inc.
Public Profile
Pharmaceutical Preparation Manufacturing
US
updated 2 months ago

Mylan, Inc. Sustainability Profile

Company website

Mylan, Inc., a global leader in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1961, Mylan has established itself as a key player in generic and specialty medications, focusing on providing high-quality, affordable healthcare solutions. The company is renowned for its extensive portfolio, which includes a wide range of generic and branded drugs, biosimilars, and over-the-counter products. Mylan's commitment to innovation and accessibility sets it apart in the competitive landscape, enabling it to serve millions of patients worldwide. With a strong market position, Mylan has achieved significant milestones, including strategic mergers and acquisitions that have expanded its global reach and product offerings. The company's dedication to improving health outcomes continues to drive its success in the ever-evolving pharmaceutical sector.

DitchCarbon Score

How does Mylan, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

45

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

31

Industry Benchmark

Mylan, Inc.'s score of 45 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.

68%

Let us know if this data was useful to you

Mylan, Inc.'s reported carbon emissions

Inherited from Viatris Inc.

Mylan, Inc., headquartered in the US, currently does not have specific carbon emissions data available, as indicated by the absence of reported figures. The company is a current subsidiary of Viatris Inc., which may influence its climate commitments and emissions reporting. As part of its corporate family relationship with Viatris Inc., Mylan's climate initiatives and targets are likely aligned with those set by Viatris. However, no specific reduction targets or climate pledges have been documented for Mylan, indicating a potential area for development in their sustainability strategy. Given the lack of direct emissions data and reduction initiatives, Mylan, Inc. may benefit from adopting industry-standard climate commitments and setting measurable targets to enhance its environmental performance.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2015201620172018201920202021202220232024
Scope 1
302,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
00,000,000
00,000,000
Scope 2
354,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
Scope 3
-
-
-
-
-
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000
0,000,000,000

How Carbon Intensive is Mylan, Inc.'s Industry?

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Mylan, Inc.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

How Carbon Intensive is Mylan, Inc.'s Location?

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Mylan, Inc. is in US, which has a low grid carbon intensity relative to other regions.

Mylan, Inc.'s Climate Goals (2030 & 2050)

Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.

Mylan, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Compare Mylan, Inc.'s Emissions with Industry Peers

Hospira

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Bristol-Myers Squibb

US
•
Pharmaceutical Preparation Manufacturing
Updated about 6 hours ago

Janssen Biotech, Inc.

US
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Pfizer

US
•
Pharmaceutical Preparation Manufacturing
Updated about 9 hours ago

Astellas Pharma Ltd.

GB
•
Pharmaceutical Preparation Manufacturing
Updated about 2 months ago

Teva Pharmaceuticals

IL
•
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Let us know if this data was useful to you

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers

Ditchcarbon
v251031.3
[email protected]+44 203 475 7875Ditch Carbon Ltd167-169 Great Portland StreetLondon W1W 5PF
UL Solutions verification badge
CDP logo
Gartner Cool Vendor 2025 badge
ProductPortalScope 3 Tool FunctionalityDataIntegrationsPricing
CustomersHaleonGrant ThorntonHikmaRead all stories
SolutionsProcurement teamsSustainability teamsPlatform ownersCarbon accountants
ResourcesCalculation MethodologyDocumentationBlogFAQOrganizationsIndustriesSBTI APITrust CentreChangelog
AboutTeamCareersLicense AgreementPrivacy